Financial Performance - The company's revenue for Q3 2023 was CNY 56,408,922.96, a decrease of 16.54% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was CNY 10,970,738.79, down 3.63% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 8,001,762.19, a decline of 12.40% compared to the previous year[5]. - Total revenue for the third quarter was CNY 170,495,925.88, a decrease of 7.4% compared to CNY 184,214,108.46 in the same period last year[22]. - Total operating costs amounted to CNY 143,337,161.46, down 4.0% from CNY 149,349,990.25 year-over-year[22]. - The net profit for Q3 2023 was CNY 41,294,028.25, representing a 28.6% increase compared to CNY 32,119,674.46 in Q3 2022[23]. - Basic and diluted earnings per share increased to CNY 0.5110 from CNY 0.4209, reflecting a growth of 21.5% year-over-year[24]. - Operating profit for the quarter was CNY 47,960,575.65, up 20.5% from CNY 39,612,741.18 in the same period last year[23]. - The total profit for the quarter was CNY 47,813,334.86, which is a 24.0% increase from CNY 38,585,579.35 in the same quarter last year[23]. - The company reported a decrease in cash received from sales of goods and services to CNY 195,456,109.30 from CNY 211,880,575.91, a decline of 7.7% year-over-year[24]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was CNY 31,132,671.06, representing a significant decrease of 37.07%[8]. - Cash flow from operating activities generated a net amount of CNY 31,132,671.06, down 37.1% from CNY 49,472,777.42 in Q3 2022[25]. - The total cash and cash equivalents at the end of the period stood at CNY 231,445,127.20, compared to CNY 189,575,322.78 at the end of Q3 2022, marking an increase of 22.1%[25]. - Cash and cash equivalents increased to CNY 232,005,069.60 from CNY 202,779,648.02 at the start of the year, representing a growth of 14.3%[20]. - The net cash flow from investment activities was CNY 11,020,283.95, a turnaround from a negative CNY 389,299,803.05 in Q3 2022[25]. - The total cash inflow from investment activities was CNY 1,019,259,001.30, significantly higher than CNY 498,783,198.62 in the previous year[25]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,194[10]. - The top ten unrestricted shareholders hold a total of 22,850,809 shares, with the largest shareholder, Dingdian Investment Management, holding 7,639,054 shares[14]. - The company’s major shareholder, Guotou High-Tech Investment Co., Ltd., holds 5,118,797 shares[14]. - The company’s stockholder, Shi Shilin, holds a total of 1,488,254 shares, with part held through a margin trading account[14]. - The company has a consistent action relationship among major shareholders, including Dingdian Investment and Guohongsheng[14]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,029,265,543.50, an increase of 1.21% from the end of the previous year[5]. - The company's total assets as of September 30, 2023, were CNY 1,029,265,543.50, up from CNY 1,017,003,454.64 at the beginning of the year[20]. - The total liabilities decreased to CNY 55,610,519.80 from CNY 71,713,828.31, a reduction of 22.5%[21]. - The company's equity attributable to shareholders rose to CNY 973,655,023.70, an increase of 3.0% from CNY 945,289,626.33[21]. - The equity attributable to shareholders at the end of the reporting period was CNY 973,655,023.70, up 3.00% from the previous year[5]. Research and Development - Research and development expenses increased to CNY 5,227,257.77, reflecting a rise of 27.7% compared to CNY 4,096,854.54 in the previous year[22]. Corporate Actions - The company established a wholly-owned subsidiary, Xidian (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., with a capital of RMB 20 million[16]. - The company held its second extraordinary general meeting on August 3, 2023, electing a new board of directors and supervisory board[15]. - The company has completed the registration procedures for its new subsidiary in Zhuhai, obtaining a business license[16]. - The company reported a total of 60,602,957 restricted shares, with 37,827,148 shares released during the period[14]. - The company’s restricted shares include those held by directors and senior management, with specific unlocking dates set[14]. - The company’s total number of restricted shares at the end of the period was 19,627,034, with no new restrictions added[13]. Miscellaneous - The company received government subsidies amounting to CNY 843,230.19 during the reporting period[6]. - The weighted average return on equity for the year-to-date was 4.29%, an increase of 0.49% compared to the previous year[5]. - The company did not undergo an audit for the Q3 report, which was released on October 25, 2023[26].
西点药业(301130) - 2023 Q3 - 季度财报